BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, June 15, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 15, 2009

View Archived Issues

Adenoviral delivery of alpha-sarcoglycan may be a promising therapy for muscular dystrophy

Read More

Botulinum toxin type B safe over 7 years in patients with cervical dystonia

Read More

Glycopyrronium bromide significantly improves sialorrhea in Parkinson's disease patients

Read More

AstraZeneca discloses novel prostaglandin E synthase-1 inhibitors for osteoarthritis therapy

Read More

Schering-Plough describes RNA-directed RNA polymerase inhibitors for the treatment of hepatitis C

Read More

Cis-urocanic acid emulsion improves skin barrier function in acute irritant dermatitis phase I study

Read More

DMMET-01 improves metabolic control in naive type 2 diabetes patients

Read More

3-Month extension of review period expected for Intermezzo NDA

Read More

Millennium Pharmaceuticals claims IKK-2 inhibitors for the treatment of rheumatoid arthritis

Read More

Bristol-Myers Squibb describes NS5B polymerase inhibitors for HCV

Read More

RGI-2001 in combination with low-dose sirolimus induces donor-specific transplantation tolerance

Read More

AEterna opens extended study for cetrorelix in benign prostatic hyperplasia

Read More

Cytos initiates combined phase I/IIa study with anti-interleukin-1 beta vaccine

Read More

Caldolor is first FDA approved intravenous therapy for fever

Read More

ImmunoGen seeks to outlicense discontinued compound IMGN-242

Read More

Modigene approves company name change to Prolor Biotech

Read More

Abraxane now available in China

Read More

Xenon and Merck & Co. establish cardiovascular strategic alliance

Read More

Takeda presents 5-HT2C receptor agonists for the treatment of obesity

Read More

G-15, a highly selective GRP30 antagonist, may be useful in the regulation of estrogen signaling

Read More

Genzyme receives European approval of Renvela for chronic kidney disease

Read More

Icagen completes enrollment in phase II senicapoc trial in exercise-induced asthma

Read More

FDA expected to approve REMS for Meda's cancer pain drug Onsolis in summer 2009

Read More

Merck & Co. to update prescribing information for Singulair following FDA communication

Read More

BSI and Lohocla sign licensing agreement for alcoholism liver disease biomarkers

Read More

Archimedes and Almac sign licensing and development agreement for granisetron product

Read More

St. Jude Medical to sponsor CABANA trial of catheter ablation in atrial fibrillation

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 15, 2026.
  • Neck exam

    Ethyreal launches to treat the underlying cause of Graves’, TED

    BioWorld
    Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
  • Illustration of Lactobacillus

    Microbiota modulates the antidepressant effects of GLP-1 analogues

    BioWorld Science
    Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
  • Microscopic image of chronic myeloid leukemia

    Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid

    BioWorld
    Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...
  • Genome sequence map

    EHA 2026: With new lenses, a changing view on pediatric cancers

    BioWorld
    In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing